Conduit Pharmaceuticals Inc. (NASDAQ:CDT) — Market Cap & Net Worth
Market Cap & Net Worth: Conduit Pharmaceuticals Inc. (CDT)
Conduit Pharmaceuticals Inc. (NASDAQ:CDT) has a market capitalization of $10.67 Million ($10.67 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26724 globally and #5326 in its home market, demonstrating a -23.65% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Conduit Pharmaceuticals Inc.'s stock price $2.26 by its total outstanding shares 4722450 (4.72 Million). Analyse Conduit Pharmaceuticals Inc. (CDT) cash flow conversion to see how efficiently the company converts income to cash.
Conduit Pharmaceuticals Inc. Market Cap History: 2022 to 2026
Conduit Pharmaceuticals Inc.'s market capitalization history from 2022 to 2026. Data shows change from $48.41 Million to $10.67 Million (-30.35% CAGR).
Index Memberships
Conduit Pharmaceuticals Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #771 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2527 of 3165 |
Weight: Conduit Pharmaceuticals Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Conduit Pharmaceuticals Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Conduit Pharmaceuticals Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Conduit Pharmaceuticals Inc.'s market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.03x
Conduit Pharmaceuticals Inc.'s market cap is 0.03 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $323.96K | $922.22 Million | -$17.80 Million | 0.00x | N/A |
| 2025 | $6.04 Million | $2.72 Billion | $237.52 Million | 0.00x | 0.03x |
Competitor Companies of CDT by Market Capitalization
Companies near Conduit Pharmaceuticals Inc. in the global market cap rankings as of May 4, 2026.
Key companies related to Conduit Pharmaceuticals Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Conduit Pharmaceuticals Inc. Historical Marketcap From 2022 to 2026
Between 2022 and today, Conduit Pharmaceuticals Inc.'s market cap moved from $48.41 Million to $ 10.67 Million, with a yearly change of -30.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $10.67 Million | +76.56% |
| 2025 | $6.04 Million | +1765.89% |
| 2024 | $323.96K | -98.49% |
| 2023 | $21.49 Million | -55.61% |
| 2022 | $48.41 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Conduit Pharmaceuticals Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.67 Million USD |
| MoneyControl | $10.67 Million USD |
| MarketWatch | $10.67 Million USD |
| marketcap.company | $10.67 Million USD |
| Reuters | $10.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Conduit Pharmaceuticals Inc.
CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, whic… Read more